PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS

S. Kaye; B. Kaufman; J. Lubinski; U. Matulonis; C. Gourley; B. Karlan; D. Taylor; M. Wickens; J. Carmichael

PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS

S. Kaye, B. Kaufman, J. Lubinski, U. Matulonis, C. Gourley, B. Karlan, D. Taylor, M. Wickens, J. Carmichael

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	304-304
Number of pages	1
Journal	Annals of Oncology
Volume	21
Publication status	Published - Oct 2010

Cite this

@article{02f73a90c2834dbfacb9dafffd0585f1,

title = "PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS",

author = "S. Kaye and B. Kaufman and J. Lubinski and U. Matulonis and C. Gourley and B. Karlan and D. Taylor and M. Wickens and J. Carmichael",

year = "2010",

month = oct,

language = "English",

volume = "21",

pages = "304--304",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

}

TY - JOUR

T1 - PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS

AU - Kaye, S.

AU - Kaufman, B.

AU - Lubinski, J.

AU - Matulonis, U.

AU - Gourley, C.

AU - Karlan, B.

AU - Taylor, D.

AU - Wickens, M.

AU - Carmichael, J.

PY - 2010/10

Y1 - 2010/10

M3 - Meeting abstract

VL - 21

SP - 304

EP - 304

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -